Trial Profile
A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory FLT3-ITD Positive Acute Myeloid Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Pexidartinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Inc; Plexxikon
- 08 Jun 2021 Patient samples from this study were used to perform capture-based sequencing of 585 malignancy-associated genes, published in the Clinical Cancer Research
- 04 Apr 2018 Status changed from active, no longer recruiting to completed.
- 31 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jan 2018.